AbbVie/Genmab’s Epkinly halves progression risk in frontline DLBCL trial

A Phase 3 study of the bispecific antibody Epkinly combined with standard chemotherapy showed nearly a 50% reduction in the risk of disease progression or death compared with chemotherapy alone in patients with newly diagnosed diffuse large B‑cell lymphoma (DLBCL).\n\nThe results exceeded analyst expectations, outperformed a competing Roche regimen, and position Epkinly to become the first bispecific therapy approved for first‑line treatment of DLBCL.\n\nGenmab, which shares ownership of Epkinly with AbbVie, reported $312 million in global net sales of the drug in the first half of the year, and its shares rose as much as 14% after the data were released.\n\nThe trial adds to a growing portfolio of bispecific antibodies that are reshaping care for blood cancers by linking diseased B cells to T cells to trigger an immune response.